Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Department of Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

1 abstract

Abstract
IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.
Org: Department of Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Florida Cancer Specialists & Research Institute, Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University,